TVAR live edited broadcasts are safe.

Original title: The impact of live transmition on patients outcomes during transcatheter aortic valve replacement: Results fron the VERITAS study. Reference: Ron Waskman, et al. Cardiovascular Revascularization Medicine 2014;15:63-68

 

With the advancement of medical technology and the great development of telecommunications, performing live or edited cases has become a common occurrence in medical education, but one of the points of discussion was always the safety of these procedures. This is a multicentre, retrospective observational case-control study. The endpoint of this analysis was the safety of patients receiving percutaneous aortic valve replacement (TVAR) during live broadcasts. Valves used were, for femoral access CoreValve and for femoral or apical access, Edwards SAPIEN. Patients receiving TVAR during a live broadcast were compared with a control group using the following criteria; STS ± 2 points, day of the procedure ±4 weeks, same first surgeon and the same access resulting one control group of 46 patients and live stream group of 46 patients. The safety endpoint was evaluated by the rate of major complications: hospital death, stroke, tamponade, embolization, coronary obstruction, renal failure requiring dialysis and need for pacemaker.

No clinical or echocardiographic results from the group live stream versus the control group were observed. The total duration of the procedure was higher in the live broadcast group (129 ± 49 versus 100 ± 42 minutes p = 0.007) but no difference in fluoroscopy time, number of surgeons, intra procedural complications, stay in coronary unit or hospital. The presence of moderate or severe aortic regurgitation was 4.7 % in the live stream group and 9.5 % in the control group without reaching statistical significance. There were no differences in the safety endpoint, death (2.2 % in each group), conversion to surgery, vascular complications, bleeding, arrhythmias, need for pacemaker or dialysis infections.

Conclusion

These data provide support that procedures of percutaneous aortic valve replacement live broadcast for congress made

More articles by this author

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

ACC 2025 | BHF PROTECT-TAVI: Are Cerebral Protection Systems Necessary in TAVI?

TAVI has seen a steady increase in use, though stroke continues to be one of its unwanted complications, mostly ischemic and, less frequently, hemorrhagic. The...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...